Amgen Meets Primary Endpoint in Phase 3 Trial of Gastric Cancer Treatment

Published: 2025-06-30 09:54:17 ET AMGN

Published on 06/30/2025 at 09:54, updated on 06/30/2025 at 09:55

By Connor Hart

Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis.

The biotechnology company said Monday that bemarituzumab, used in combination with chemotherapy, showed a statistically significant and clinically meaningful improvement in overall survival, compared with placebo plus chemotherapy in patients with certain types of gastric or gastroesophageal junction cancer.

"Most patients with gastric cancer are diagnosed at an advanced stage, with poor prognosis, low survival rates and limited therapeutic options," Jay Bradner, executive vice president of research and development at Amgen, said.

The positive top-line results from the recent study "mark a meaningful advance in the development of effective targeted therapy for gastric cancer," he added.

A Phase 3 study of bemarituzumab, used in combination with chemotherapy and existing cancer treatment nivolumab, is also ongoing in patients with first-line gastric cancer. The company expects to release data from the study later this year.

Write to Connor Hart at [email protected]

(END) Dow Jones Newswires

06-30-25 0953ET